A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Giorgio V. Scagliotti, Denis Moro‐Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te‐Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaron M. Gruver, Johan Wallin, Kambiz Mansouri, Volker Wacheck, Gee‐Chen Chang
Médium: Artigo
Jazyk:angličtina
Vydáno: 2019
On-line přístup:https://doi.org/10.1016/j.jtho.2019.10.003
http://www.jto.org/article/S1556086419335300/pdf
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1016/j.jtho.2019.10.003
http://www.jto.org/article/S1556086419335300/pdf

Podobné jednotky